Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 3/1997

01-09-1997

A phase II Southwest Oncology Group study of cisplatin and continuous infusion vinblastine in the treatment of advanced soft tissue sarcoma

Authors: Mary Lou Keohan, Michael R. Grever, Stanley P. Balcerzak, Karen Antman

Published in: Investigational New Drugs | Issue 3/1997

Login to get access
Metadata
Title
A phase II Southwest Oncology Group study of cisplatin and continuous infusion vinblastine in the treatment of advanced soft tissue sarcoma
Authors
Mary Lou Keohan
Michael R. Grever
Stanley P. Balcerzak
Karen Antman
Publication date
01-09-1997
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 3/1997
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/A:1005803921371

Other articles of this Issue 3/1997

Investigational New Drugs 3/1997 Go to the issue

OriginalPaper

A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors

OriginalPaper

Early evaluation of liposomal daunorubicin (DaunoXome®, Nexstar) in the treatment of relapsed and refractory lymphoma

OriginalPaper

Phase II trial of topotecan in advanced gastric cancer: A Southwest Oncology Group study

OriginalPaper

Unusual central nervous system toxicity in a phase I study of N1N11diethylnorspermine in patients with advanced malignancy

OriginalPaper

Matrix metalloproteinase inhibitors: Present achievements and future prospects

OriginalPaper

Preclinical pharmacokinetic, antitumor and toxicity studies with CL-994 (N-acetyldinaline)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits